SG10201913359TA - Combination therapies for melanoma comprising administering cobimetinib and vemurafinib - Google Patents
Combination therapies for melanoma comprising administering cobimetinib and vemurafinibInfo
- Publication number
- SG10201913359TA SG10201913359TA SG10201913359TA SG10201913359TA SG10201913359TA SG 10201913359T A SG10201913359T A SG 10201913359TA SG 10201913359T A SG10201913359T A SG 10201913359TA SG 10201913359T A SG10201913359T A SG 10201913359TA SG 10201913359T A SG10201913359T A SG 10201913359TA
- Authority
- SG
- Singapore
- Prior art keywords
- vemurafinib
- melanoma
- combination therapies
- cobimetinib
- administering
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0241—Advertisements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Business, Economics & Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Finance (AREA)
- Strategic Management (AREA)
- Development Economics (AREA)
- Accounting & Taxation (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Business, Economics & Management (AREA)
- Marketing (AREA)
- Theoretical Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Economics (AREA)
- Game Theory and Decision Science (AREA)
- Entrepreneurship & Innovation (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261684673P | 2012-08-17 | 2012-08-17 | |
US201261705575P | 2012-09-25 | 2012-09-25 | |
US201261706026P | 2012-09-26 | 2012-09-26 | |
US201261722725P | 2012-11-05 | 2012-11-05 | |
US201361780708P | 2013-03-13 | 2013-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201913359TA true SG10201913359TA (en) | 2020-02-27 |
Family
ID=49035547
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913359TA SG10201913359TA (en) | 2012-08-17 | 2013-08-15 | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
SG10201708494QA SG10201708494QA (en) | 2012-08-17 | 2013-08-15 | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
SG11201500582UA SG11201500582UA (en) | 2012-08-17 | 2013-08-15 | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201708494QA SG10201708494QA (en) | 2012-08-17 | 2013-08-15 | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
SG11201500582UA SG11201500582UA (en) | 2012-08-17 | 2013-08-15 | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
Country Status (31)
Country | Link |
---|---|
US (3) | US11087354B2 (ru) |
EP (1) | EP2884979B1 (ru) |
JP (2) | JP6335169B2 (ru) |
KR (5) | KR20150038068A (ru) |
CN (2) | CN104640545A (ru) |
AU (1) | AU2013304021B2 (ru) |
BR (1) | BR112015003418A2 (ru) |
CA (2) | CA2879252C (ru) |
CL (1) | CL2015000345A1 (ru) |
CO (1) | CO7180225A2 (ru) |
DK (1) | DK2884979T3 (ru) |
EA (1) | EA033573B1 (ru) |
ES (1) | ES2743427T3 (ru) |
HK (1) | HK1206605A1 (ru) |
HR (1) | HRP20191533T1 (ru) |
HU (1) | HUE044789T2 (ru) |
IL (1) | IL237065B (ru) |
LT (1) | LT2884979T (ru) |
MX (1) | MX367970B (ru) |
MY (1) | MY180613A (ru) |
NZ (1) | NZ744862A (ru) |
PE (1) | PE20151156A1 (ru) |
PH (1) | PH12015500186A1 (ru) |
PL (1) | PL2884979T3 (ru) |
PT (1) | PT2884979T (ru) |
RS (1) | RS59113B1 (ru) |
SG (3) | SG10201913359TA (ru) |
SI (1) | SI2884979T1 (ru) |
UA (1) | UA114923C2 (ru) |
WO (1) | WO2014027056A1 (ru) |
ZA (1) | ZA201500348B (ru) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2879252C (en) * | 2012-08-17 | 2017-10-10 | F. Hoffmann-La Roche Ag | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
CN107073121A (zh) * | 2014-06-13 | 2017-08-18 | 基因泰克公司 | 治疗及预防癌症药物抗性的方法 |
CZ2015250A3 (cs) * | 2015-04-14 | 2016-10-26 | Zentiva, K.S. | Amorfní formy vemurafenibu |
WO2016191296A1 (en) * | 2015-05-22 | 2016-12-01 | Plexxikon Inc. | Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases |
SI3881833T1 (sl) * | 2015-06-30 | 2024-03-29 | Genentech, Inc., | Tablete s takojšnjim sproščanjem, ki vsebujejo zdravilo in postopek za oblikovanje tablet |
BR112018008882A8 (pt) | 2015-11-03 | 2019-02-26 | Univ Texas | método para tratar um distúrbio proliferativo e produto farmacêutico |
AU2016355320B2 (en) * | 2015-11-19 | 2023-12-07 | Genentech, Inc. | Methods of treating cancer using B-RAF inhibitors and immune checkpoint inhibitors |
WO2017095826A1 (en) * | 2015-11-30 | 2017-06-08 | The Regents Of The University Of California | Combination therapy for treatment of melanoma |
EP3496752B1 (en) | 2016-08-12 | 2022-05-18 | Genentech, Inc. | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor |
KR20190061030A (ko) | 2016-09-29 | 2019-06-04 | 제넨테크, 인크. | Mek 억제제, pd-1 축 억제제 및 탁산을 사용한 조합 요법 |
JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
US11395823B2 (en) | 2018-01-09 | 2022-07-26 | Duke University | Topical administration of MEK inhibiting agents for the treatment of skin disorders |
CN109879855B (zh) * | 2019-03-26 | 2021-01-05 | 中国医学科学院医药生物技术研究所 | 靶向肿瘤细胞表面pd-l1分子的抑制剂及其应用 |
WO2021229439A1 (en) * | 2020-05-12 | 2021-11-18 | Novartis Ag | Therapeutic combinations comprising a craf inhibitor |
EP4304592A1 (en) | 2021-03-09 | 2024-01-17 | Genentech, Inc. | Belvarafenib for use in treatment of brain cancers |
JP2024514112A (ja) | 2021-04-06 | 2024-03-28 | ジェネンテック, インコーポレイテッド | ベルバラフェニブおよびコビメチニブを用いた併用療法、またはベルバラフェニブ、コビメチニブおよびアテゾリズマブを用いた併用療法 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2466762A1 (en) | 2001-12-04 | 2003-06-12 | Onyx Pharmaceuticals, Inc. | Raf-mek-erk pathway inhibitors to treat cancer |
NZ535158A (en) | 2002-03-13 | 2007-06-29 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
WO2005047542A1 (en) | 2003-10-16 | 2005-05-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Treatments for inhibiting development and progression of nevi and melanoma having braf mutations |
WO2005051906A2 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
PT1696920E (pt) | 2003-12-19 | 2015-01-14 | Plexxikon Inc | Compostos e métodos para o desenvolvimento de moduladores de ret |
US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
US20060216288A1 (en) | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
RS52010B (en) | 2005-06-22 | 2012-04-30 | Plexxikon Inc. | DERIVATI PIROLO [2, 3-B] PIRIDINA KAO INHIBITORI PROTEIN KINAZE |
PL1913157T5 (pl) | 2005-06-28 | 2017-09-29 | Genentech Inc | Mutacje EGFR i KRAS do prognozowania reakcji pacjenta na leczenie inhibitorem EGFR |
US9095581B2 (en) | 2005-07-21 | 2015-08-04 | Ardea Biosciences, Inc. | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof |
US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
WO2007013997A2 (en) | 2005-07-22 | 2007-02-01 | H. Lee Moffitt Cancer Center And Research Institute | Inhibition of the raf/mek/p-erk pathway for treating cancer |
JP5129143B2 (ja) | 2005-10-07 | 2013-01-23 | エグゼリクシス, インコーポレイテッド | Mekインヒビターおよびその使用方法 |
AR062760A1 (es) * | 2006-09-13 | 2008-12-03 | Takeda Pharmaceutical | Administracion de inhibidores de dipeptidilpetidasa |
EP2074226A2 (en) | 2006-09-19 | 2009-07-01 | Novartis AG | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors |
CN101605540A (zh) | 2006-12-14 | 2009-12-16 | 埃克塞利希斯股份有限公司 | 使用mek抑制剂的方法 |
PE20090690A1 (es) | 2007-03-13 | 2009-06-22 | Amgen Inc | Mutaciones de k-ras y b-raf y terapia con anticuerpos anti-egfr |
WO2008120004A1 (en) | 2007-04-02 | 2008-10-09 | Astrazeneca Ab | Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer |
JP5479337B2 (ja) | 2007-07-30 | 2014-04-23 | アルディア バイオサイエンス,インク. | Mek阻害剤およびrafキナーゼ阻害剤の組み合わせ、ならびにその使用 |
CA2716947A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
WO2009111280A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
CL2009000448A1 (es) | 2008-02-29 | 2009-11-27 | Genentech Inc | Compuestos derivados de 3-sulfonilamino-n-(1h-pirazolo-[3,4-b]piridin-5il)benzamida; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento del cancer, tal como sarcoma, carcinoma, adenoma, entre otros. |
CN102015707A (zh) | 2008-02-29 | 2011-04-13 | 阵列生物制药公司 | Raf抑制剂化合物及其使用方法 |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
DE102008059206A1 (de) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
EP2414356B1 (en) * | 2009-04-03 | 2015-09-02 | F.Hoffmann-La Roche Ag | Propane-i-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof |
BR112012003926A2 (pt) | 2009-08-24 | 2020-08-11 | Genentech Inc | método para identificar um paciente não responsivo ao tratamento com um inibidor de b-raf, método para determinar se um tumor irá responder ao tratamento com um inibidor de b-raf, método para predizer se um paciente será não responsivo ao tratamento com um inibidor de braf específico, kit, método para classificar um tumor de mama, pulmão, cólon, ovário, tiroide, melanoma, ou pancreático e método para identificar um tumor não responsivo ao tratamento com um inibidor de b-raf |
AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
JP2013507415A (ja) | 2009-10-12 | 2013-03-04 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Pi3k阻害剤とmek阻害剤の併用 |
KR20120097496A (ko) | 2009-10-12 | 2012-09-04 | 글락소스미스클라인 엘엘씨 | 조합물 |
WO2011104694A2 (en) * | 2010-02-26 | 2011-09-01 | GAMMAGENETICS Sàrl | Detection of braf v600e mutation by allele specific real time quantitative pcr (as-qpcr) using locked nucleic acids primers and beacon probes |
JP5985401B2 (ja) | 2010-03-09 | 2016-09-06 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 第一の癌療法に対する耐性を現に有するか、または、そのような耐性を生じる患者において癌を診断および治療する方法 |
US20120045433A1 (en) | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
US8426418B2 (en) | 2010-08-27 | 2013-04-23 | CollabRx Inc. | Method to treat melanoma in BRAF inhibitor-resistant subjects |
WO2012031124A2 (en) * | 2010-09-03 | 2012-03-08 | Bristol-Myers Squibb Company | Drug formulations using water soluble antioxidants |
EP2635286A4 (en) | 2010-11-05 | 2014-11-12 | Glaxosmithkline Ip No 2 Ltd | METHOD FOR THE TREATMENT OF CANCER |
WO2012068562A2 (en) * | 2010-11-19 | 2012-05-24 | The Regents Of The University Of California | Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas |
JP2013543008A (ja) | 2010-11-19 | 2013-11-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッド | Braf阻害剤による治療方法 |
US9295669B2 (en) * | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產(第二)有限公司 | 新穎醫藥組成物 |
AR085279A1 (es) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico |
WO2012145503A1 (en) | 2011-04-21 | 2012-10-26 | Novartis Ag | Pharmaceutical combinations |
US20130172375A1 (en) | 2011-12-13 | 2013-07-04 | Hoffmann-La Roche Inc. | Pharmaceutical composition |
US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
CA2879252C (en) * | 2012-08-17 | 2017-10-10 | F. Hoffmann-La Roche Ag | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
BR112015018418A2 (pt) | 2013-02-22 | 2017-07-18 | Hoffmann La Roche | métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico |
-
2013
- 2013-08-15 CA CA2879252A patent/CA2879252C/en active Active
- 2013-08-15 RS RS20191053A patent/RS59113B1/sr unknown
- 2013-08-15 KR KR1020157003834A patent/KR20150038068A/ko active Search and Examination
- 2013-08-15 BR BR112015003418A patent/BR112015003418A2/pt not_active IP Right Cessation
- 2013-08-15 SG SG10201913359TA patent/SG10201913359TA/en unknown
- 2013-08-15 CA CA2928396A patent/CA2928396A1/en not_active Abandoned
- 2013-08-15 NZ NZ744862A patent/NZ744862A/en unknown
- 2013-08-15 AU AU2013304021A patent/AU2013304021B2/en active Active
- 2013-08-15 HU HUE13753131 patent/HUE044789T2/hu unknown
- 2013-08-15 MX MX2015002031A patent/MX367970B/es active IP Right Grant
- 2013-08-15 ES ES13753131T patent/ES2743427T3/es active Active
- 2013-08-15 CN CN201380042815.XA patent/CN104640545A/zh active Pending
- 2013-08-15 EP EP13753131.5A patent/EP2884979B1/en active Active
- 2013-08-15 KR KR1020227041809A patent/KR20220165811A/ko not_active IP Right Cessation
- 2013-08-15 UA UAA201501710A patent/UA114923C2/uk unknown
- 2013-08-15 KR KR1020197014117A patent/KR20190057421A/ko active Application Filing
- 2013-08-15 SG SG10201708494QA patent/SG10201708494QA/en unknown
- 2013-08-15 SI SI201331565T patent/SI2884979T1/sl unknown
- 2013-08-15 CN CN201910437096.0A patent/CN110251512A/zh active Pending
- 2013-08-15 JP JP2015526987A patent/JP6335169B2/ja active Active
- 2013-08-15 SG SG11201500582UA patent/SG11201500582UA/en unknown
- 2013-08-15 EA EA201590262A patent/EA033573B1/ru not_active IP Right Cessation
- 2013-08-15 MY MYPI2015700457A patent/MY180613A/en unknown
- 2013-08-15 KR KR1020177009790A patent/KR20170044759A/ko active Search and Examination
- 2013-08-15 PE PE2015000215A patent/PE20151156A1/es not_active Application Discontinuation
- 2013-08-15 DK DK13753131.5T patent/DK2884979T3/da active
- 2013-08-15 US US13/967,782 patent/US11087354B2/en active Active
- 2013-08-15 WO PCT/EP2013/067050 patent/WO2014027056A1/en active Application Filing
- 2013-08-15 PT PT13753131T patent/PT2884979T/pt unknown
- 2013-08-15 PL PL13753131T patent/PL2884979T3/pl unknown
- 2013-08-15 LT LTEP13753131.5T patent/LT2884979T/lt unknown
- 2013-08-15 KR KR1020217027317A patent/KR20210108502A/ko not_active IP Right Cessation
-
2015
- 2015-01-16 ZA ZA2015/00348A patent/ZA201500348B/en unknown
- 2015-01-27 CO CO15016085A patent/CO7180225A2/es unknown
- 2015-01-28 PH PH12015500186A patent/PH12015500186A1/en unknown
- 2015-02-02 IL IL237065A patent/IL237065B/en active IP Right Grant
- 2015-02-13 CL CL2015000345A patent/CL2015000345A1/es unknown
- 2015-07-27 HK HK15107148.9A patent/HK1206605A1/xx unknown
-
2017
- 2017-04-06 JP JP2017075880A patent/JP2017160214A/ja active Pending
-
2019
- 2019-08-27 HR HRP20191533 patent/HRP20191533T1/hr unknown
-
2021
- 2021-08-09 US US17/444,691 patent/US11783366B2/en active Active
-
2023
- 2023-08-17 US US18/451,452 patent/US20240046303A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1206605A1 (en) | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib cobimetinib | |
HK1202545A1 (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
HK1211475A1 (en) | Combination therapy | |
HK1205298A1 (en) | Hardware and software association and authentication | |
HK1203493A1 (en) | Substituted azabicycles and use thereof | |
EP2884984A4 (en) | THERAPEUTIC COMPOSITIONS AND METHOD | |
EP2806918A4 (en) | PROCESSES AND DEVICES FOR SPRAYING WITH AUTOMATIC RINSING | |
EP2867209A4 (en) | COMPOUNDS AND THEIR THERAPEUTIC USES | |
PT2914254T (pt) | Terapias de combinação para tratar cancros quimiorresistentes | |
EP2875014A4 (en) | ANTI-MUCUS MEDICAMENTS AND USES THEREOF | |
GB201216649D0 (en) | Agents and methods | |
GB201217439D0 (en) | Combination therapy | |
HK1203198A1 (en) | Substituted phenylimidazopyrazoles and use thereof | |
HK1217688A1 (zh) | -氯- 苯基- -茚- -酮及其用途 | |
HK1210426A1 (en) | Combination therapy | |
EP2895186A4 (en) | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | |
EP2817004A4 (en) | BOUVARDIN DERIVATIVES AND THEIR THERAPEUTIC USES | |
HK1207154A1 (en) | C1q-adiponectin complex and use thereof c1q- | |
GB201222541D0 (en) | Kiddibidet and pottibidet | |
GB201214493D0 (en) | Therapies | |
IL218974A0 (en) | Conaction bitwen coutch and playels | |
GB201202945D0 (en) | Novel cancer therapies and methods | |
GB201202021D0 (en) | Co-sleeper and breastfeeder | |
EP2922862A4 (en) | COMPLEX FORMING MODULATING ACTIVE SUBSTANCES AND USES THEREOF | |
GB201418806D0 (en) | Generating and partitioning polynomials |